|It's a bit ironic that the only NR IPA has issued about signing a large pharmaceutical co is this one, a top 15 for its hibridoma platform and not B cell Select(tm) or DeepDisplay (tm). |
It's the B cell Select platform that is the most prominent platform that's caught the attention of multiple majors (direct view into B cells to show much greater depth allowing the selection of many more candidates vs traditional B cell discovery methods.
Anyway, this agreement from last October serves as a hint of how well rounded IPA is as a full service Antibody discovery CRO.
It's totally expected to see IPA sell off into the mid .50s after the disappointing Q4 Numbers. More discerning or perhaps less pained shareholders may have kept in mind that the quarter just reported ended one month PRIOR to this NR. Fingers crossed to see some revenues from the following programs recognized in Q1 ending July 31 and Q2. Let's break this $3m /quarter glass ceiling!